Mark A. Lemmon

Last updated

Mark Lemmon
FRS
Professor Mark Lemmon FRS (cropped).jpg
Lemmon in 2016
Born1964 (age 5960)
Norfolk, England
Education Norwich School
Alma mater
SpouseKatherine Ferguson
Scientific career
Fields
Institutions
Thesis Specific interactions between transmembrane alpha-helices: Their role in the oligomerisation of integral membrane proteins  (1993)
Doctoral advisor Donald Engelman
Website

Mark Andrew Lemmon FRS [2] (born 1964) an English-born biochemist, is the Alfred Gilman Professor and Department Chair of Pharmacology at Yale University where he also directs the Cancer Biology Institute. [1] [3] [4]

Contents

Education

Lemmon was born in Norfolk, England in 1964 and grew up in Taverham and Poringland. [5] He was educated at Norwich School (from 1976 to 1983), and then at Hertford College, Oxford, from which he graduated with a first class Bachelor of Arts (BA) degree in biochemistry in 1988. [4] He completed his PhD at Yale University as a Howard Hughes Medical Institute Predoctoral Fellow supervised by Donald Engelman [6] for research on the oligomerization of transmembrane α-helices. [7]

Research and career

Following his PhD, Lemmon was a postdoctoral researcher and fellow of the Damon Runyon Cancer Research Foundation at New York University in the laboratory of Joseph Schlessinger. [8] Following his postdoctoral research, Lemmon was recruited to the department of biochemistry and biophysics at the University of Pennsylvania Perelman School of Medicine, where he gained tenure in 2001 and became departmental chair in 2008 before moving to Yale University in 2015.

Lemmon's research combines biochemistry and structural biology with cell biology, focusing on understanding molecular mechanisms of transmembrane signalling by cell-surface growth factor receptors such as the epidermal growth factor (EGF) receptor [1] [2] and other receptor tyrosine kinases. [9] With Kathryn Ferguson and others, he also played an important role in understanding the structure and function of the Pleckstrin homology domain in phosphoinositide signalling and elsewhere.

Lemmon has made important contributions to the discovery of both normal and pathological activation mechanisms of growth factor receptors and the signalling networks that they engage within cells. He is also committed to exploiting this understanding clinically. These receptors and their downstream effectors are activated aberrantly in numerous cancers, and are important targets of cancer drugs. Lemmon's recent work has focused on the need to understand the biochemistry of oncogenic activation to use such drugs effectively. [2]

Before moving to Yale, Lemmon was George W. Raiziss Professor and Chair of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania. [2] [10] His research has been funded by the National Cancer Institute, [11] the National Institute of General Medical Sciences, and the Department of Defense Congressionally Directed Medical Research Programs. [8]

Lemmon serves on the editorial boards of several scientific journals, including Cell , Molecular Cell , Molecular and Cellular Biology , and Science Signaling .[ citation needed ] Having served as an associate editor for the Biochemical Journal for many years, he was appointed chair of the editorial board in January 2021. [12] Between 2007 and 2013, Lemmon served as secretary for the American Society for Biochemistry and Molecular Biology (ASBMB).[ citation needed ]

Awards and honours

Lemmon was elected a Fellow of the Royal Society (FRS) in 2016, [2] as an ASBMB Fellow in 2023, [13] and as a Member of the Connecticut Academy of Science and Engineering (CASE) in 2024. [14] In 2012 Lemmon was awarded the Dorothy Hodgkin prize by the Protein Society. [15]

Related Research Articles

<span class="mw-page-title-main">Tony Pawson (biochemist)</span> British-born Canadian scientist

Anthony James Pawson was a British-born Canadian genetic scientist. He was known and recognized for his work on cellular organization, including how cells respond to growth signals, and how they communicate with each other.

<span class="mw-page-title-main">Receptor tyrosine kinase</span> Class of enzymes

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. Of the 90 unique tyrosine kinase genes identified in the human genome, 58 encode receptor tyrosine kinase proteins. Receptor tyrosine kinases have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Mutations in receptor tyrosine kinases lead to activation of a series of signalling cascades which have numerous effects on protein expression. The receptors are generally activated by dimerization and substrate presentation. Receptor tyrosine kinases are part of the larger family of protein tyrosine kinases, encompassing the receptor tyrosine kinase proteins which contain a transmembrane domain, as well as the non-receptor tyrosine kinases which do not possess transmembrane domains.

<span class="mw-page-title-main">Harvey Lodish</span> American cell biologist, born 1941

Harvey Franklin Lodish is a molecular and cell biologist, professor at the Massachusetts Institute of Technology (MIT), Founding Member of the Whitehead Institute for Biomedical Research, and lead author of the textbook Molecular Cell Biology. Lodish's research focused on cell surface proteins and other important areas at the interface between molecular cell biology and medicine.

Joseph Schlessinger is a Yugoslav-born Israeli-American biochemist and biophysician. He is chair of the Pharmacology Department at Yale University School of Medicine in New Haven, Connecticut, as well as the founding director of the school's new Cancer Biology Institute. His area of research is signaling through tyrosine phosphorylation, which is important in many areas of cellular regulation, especially growth control and cancer. Schlessinger's work has led to an understanding of the mechanism of transmembrane signaling by receptor tyrosine kinases and how the resulting signals control cell growth and differentiation.

Donald Max Engelman is Higgins Professor of Biochemistry at Yale University. He is a member of the National Academy of Sciences (1997), fellow of the American Academy of Arts and Sciences, a fellow of the National Institutes of Health, and has been a Guggenheim fellow. He served as the editor of the Annual Review of Biophysics and Biophysical Chemistry (1984–1993).

<span class="mw-page-title-main">Laurence Pearl</span> British biologist

Laurence Harris Pearl FRS FMedSci is a British biochemist and structural biologist who is currently Professor of Structural Biology in the Genome Damage and Stability Centre and was Head of the School of Life Sciences at the University of Sussex.

<span class="mw-page-title-main">Bruce William Stillman</span> Australian biochemist and cancer researcher

Bruce William Stillman is a biochemist and cancer researcher who has served as the Director of Cold Spring Harbor Laboratory (CSHL) since 1994 and President since 2003. He also served as the Director of its NCI-designated Cancer Center for 25 years from 1992 to 2016. During his leadership, CSHL has been ranked as the No. 1 institution in molecular biology and genetics research by Thomson Reuters. Stillman's research focuses on how chromosomes are duplicated in human cells and in yeast Saccharomyces cerevisiae; the mechanisms that ensure accurate inheritance of genetic material from one generation to the next; and how missteps in this process lead to cancer. For his accomplishments, Stillman has received numerous awards, including the Alfred P. Sloan, Jr. Prize in 2004 and the 2010 Louisa Gross Horwitz Prize, both of which he shared with Thomas J. Kelly of Memorial Sloan-Kettering Cancer Center, as well as the 2019 Canada Gairdner International Award for biomedical research, which he shared with John Diffley.

Ralf Heinrich Adams is a biochemist and cell biologist. He is director at the Max Planck Institute for Molecular Biomedicine and head of the Department of Tissue Morphogenesis in Münster, Germany.

Natalie G. Ahn is a professor of chemistry and biochemistry at the University of Colorado at Boulder. Her research is focused on understanding the mechanisms of cell signaling, with a speciality in phosphorylation and cancers. Ahn's work uses the tools of "classical chemistry" to work on understanding the genetic code and how genetics affects life processes. She has been a professor at the University of Colorado at Boulder since 2003, where she is a distinguished professor. She was a Howard Hughes Medical Institute investigator between 1994 and 2014. In 2018, she was elected to the National Academy of Sciences and named a fellow of the American Academy of Arts and Sciences.

Tobias C. Walther is the chair of the cell biology program at Sloan Kettering Institute in New York City and a professor at Weill Cornell School of Medicine, where he co-directs the Farese and Walther lab. He has been a Howard Hughes Medical Institute investigator since 2015. His primary responsibilities are to provide leadership in research and teaching in the scientific fields of metabolism, membrane biology and lipids.

<span class="mw-page-title-main">Volker Haucke</span>

Volker Haucke is a biochemist and cell biologist. He is Director of the Leibniz-Forschungsinstitut für Molekulare Pharmakologie Berlin (FMP) Berlin and Professor of Molecular Pharmacology at the Institute for Pharmacy of the Free University of Berlin.

<span class="mw-page-title-main">Anthony R. Hunter</span> British-American biologist (born 1943)

Anthony Rex Hunter is a British-American biologist who is a professor of biology at the Salk Institute for Biological Studies and the University of California San Diego. His research publications list his name as Tony Hunter.

Sarah Spiegel is professor and chair of the Department of Biochemistry and Molecular Biology at Virginia Commonwealth University (VCU). In the mid-1990s she discovered the sphingosine-1-phosphate (S1P) molecule, a lipid which has been identified as a signaler for the spread of cancer, inflammation, and cardiovascular disease. Her research continues to focus on S1P.

Sandhya Srikant Visweswariah is a scientist and academic at the Indian Institute of Science, Bangalore, India. She was the Chairperson of the Department of Developmental Biology and Genetics and the Co-chair of the Department of Bioengineering, Indian Institute of Science. She additionally holds the position of Adjunct Professor, Faculty of Medicine and Dentistry, University of Bergen, Norway. Her research involves the investigation of the mechanism of signal transduction via cyclic nucleotides, phosphodiesterases and novel cyclases in bacteria. Most recently, she was awarded a Bill and Melinda Gates Grand Challenges Explorations Grant for her proposal entitled "A Small Animal Model of ETEC-Mediated Diarrhea".

Marion Sewer (1972-2016) was a pharmacologist and professor at the University of California, San Diego's Skaggs School of Pharmacy and Pharmaceutical Sciences known for her research on steroid hormone biogenesis and her commitment to increasing diversity in science. Much of her research centered around cytochrome P450, a family of enzymes involved in the conversion of cholesterol into steroid hormones. She died unexpectedly at the age of 43 from a pulmonary embolism on January 28, 2016, while traveling through the Detroit airport.

Alan Frederick Cowman AC, FRS, FAA, CorrFRSE, FAAHMS, FASP, FASM is an internationally acclaimed malaria researcher whose work specialises in researching the malaria-causing parasite, Plasmodium falciparum, and the molecular mechanisms it uses to evade host responses and antimalarial drugs. As of May 2024, he is the deputy directory and Laboratory Head of the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, and his laboratory continues to work on understanding how Plasmodium falciparum, infects humans and causes disease. He was elected as a fellow of the Royal Society in 2011 and awarded the Companion of the Order of Australia in 2019 for his "eminent service to the biological sciences, notably to molecular parasitology, to medical research and scientific education, and as a mentor."

Karen Renee Gibson Fleming is a Professor of Biophysics at Johns Hopkins University. She investigates the energetics of transmembrane helix-helix interactions. Fleming was awarded the 2020 Protein Society Carl Brändén Award.

<span class="mw-page-title-main">Alexandra Newton</span> US-based Protein Kinase C expert

Alexandra C. Newton is a Canadian and American biochemist. She is a Distinguished Professor of pharmacology at the University of California, San Diego. Newton runs a multidisciplinary Protein kinase C and Cell signaling biochemistry and cell biology research group in the School of Medicine, investigating molecular mechanisms of signal transduction in the Phospholipase C (PLC) and Phosphoinositide 3-kinase signaling pathways. She has been continuously funded by the US National Institutes of Health since 1988.

Yusuf Awni Hannun is an American molecular biologist, biochemist, and clinician. He is known for the discovery that sphingolipids have signaling functions.

<span class="mw-page-title-main">Susan J. Baserga</span> American physician and academic

Susan J. Baserga is an American physician who is the William H. Fleming Professor of Molecular Biophysics and Biochemistry at Yale University. Her research considers the molecular basis of ribosomes, and the mechanistic basis of inherited human disease.

References

  1. 1 2 3 4 Mark A. Lemmon publications indexed by Google Scholar OOjs UI icon edit-ltr-progressive.svg
  2. 1 2 3 4 5 Anon (2016). "Professor Mark Lemmon FRS". London: Royal Society. Archived from the original on 29 April 2016. One or more of the preceding sentences incorporates text from the royalsociety.org website where:
    "All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License." -- "Royal Society Terms, conditions and policies". Archived from the original on 25 September 2015. Retrieved 9 March 2016.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  3. Mark A. Lemmon publications indexed by the Scopus bibliographic database. (subscription required)
  4. 1 2 "Mark Andrew Lemmon, PhD: Professor of Pharmacology; Director, Cancer Biology Institute". yale.edu. Yale University. Archived from the original on 21 April 2016.
  5. Cope, Lauren (2016). "Former Norwich pupil and UEA lecturer elected as Fellows into the prestigious Royal Society for scientists". edp24.co.uk. Eastern Daily Press. Archived from the original on 18 December 2018.
  6. Lemmon, Mark A.; Flanagan, John M.; Treutlein, Herbert R.; Zhang, Jian; Engelman, Donald M. (1992). "Sequence specificity in the dimerization of transmembrane .alpha.-helixes". Biochemistry. 31 (51): 12719–12725. doi:10.1021/bi00166a002. PMID   1463743.
  7. Lemmon, Mark Andrew (1993). Specific interactions between transmembrane alpha-helices: Their role in the oligomerization of integral membrane proteins. search.library.yale.edu (PhD thesis). Yale University.(subscription required)
  8. 1 2 Mark Lemmon's ORCID   0000-0002-3379-5319
  9. Lemmon, Mark Andrew; Schlessinger, Joseph (2010). "Cell Signaling by Receptor Tyrosine Kinases". Cell. 141 (7): 1117–1134. doi:10.1016/j.cell.2010.06.011. PMC   2914105 . PMID   20602996.
  10. "Mark Andrew Lemmon". Pennsylvania: upenn.edu. Archived from the original on 16 May 2016.
  11. "Mark Lemmon, co-director of the Yale Cancer Biology Institute, talks about how a National Cancer Ins". youtube.com.
  12. "Mark Lemmon at the Biochemical Journal". biochemj.org. Portland Press.
  13. "ASBMB names 2023 fellows".
  14. "Connecticut Academy of Science and Engineering Elects 35 New Members in 2024". 28 February 2024.
  15. Anon (2013). "The Dorothy Crowfoot Hodgkin Award". proteinsociety.org. Protein Society. Archived from the original on 5 August 2013.